• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 5. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473

Recent Advances in the Study of 2-(3-Chlorobenzenesulfonamido)-3-methylbutanoic acid (CAS: 1009549-57-8)

2-(3-Chlorobenzenesulfonamido)-3-methylbutanoic acid (CAS: 1009549-57-8) has recently emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This sulfonamide derivative has shown promising potential in various therapeutic applications, particularly in the modulation of enzymatic activity and as a scaffold for drug development. Recent studies have focused on its synthesis, structural characterization, and biological evaluation, shedding light on its mechanism of action and potential clinical applications.

One of the key areas of research has been the compound's role as an inhibitor of specific enzymes involved in inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 2-(3-chlorobenzenesulfonamido)-3-methylbutanoic acid exhibits potent inhibitory activity against cyclooxygenase-2 (COX-2), with an IC50 value of 0.8 μM. The study utilized X-ray crystallography to elucidate the binding mode of the compound within the COX-2 active site, revealing critical interactions with key amino acid residues. This structural insight provides a foundation for the design of more selective and potent COX-2 inhibitors.

In addition to its anti-inflammatory properties, recent investigations have explored the compound's potential in oncology. A preclinical study conducted by researchers at the National Cancer Institute found that 2-(3-chlorobenzenesulfonamido)-3-methylbutanoic acid induces apoptosis in certain cancer cell lines through the activation of the intrinsic mitochondrial pathway. The compound was shown to upregulate pro-apoptotic proteins such as Bax while downregulating anti-apoptotic Bcl-2, suggesting a novel mechanism for cancer therapy. These findings were published in the journal Cancer Research in early 2024.

The pharmacokinetic profile of 2-(3-chlorobenzenesulfonamido)-3-methylbutanoic acid has also been a subject of recent investigation. A 2024 pharmacokinetic study in animal models reported favorable oral bioavailability (approximately 65%) and a half-life of 4.2 hours, making it a promising candidate for further development. The study, published in the European Journal of Pharmaceutical Sciences, also noted that the compound demonstrates good blood-brain barrier penetration, opening possibilities for central nervous system applications.

From a synthetic chemistry perspective, recent advances have focused on optimizing the production of 2-(3-chlorobenzenesulfonamido)-3-methylbutanoic acid. A green chemistry approach published in Organic Process Research & Development in 2023 described an improved synthetic route with higher yields (85% compared to previous 62%) and reduced environmental impact. The new method employs water as the primary solvent and eliminates the need for hazardous reagents, addressing important considerations for scalable production.

Looking forward, the diverse biological activities and favorable physicochemical properties of 2-(3-chlorobenzenesulfonamido)-3-methylbutanoic acid position it as a versatile lead compound for multiple therapeutic areas. Current research efforts are focusing on structural modifications to enhance potency and selectivity, as well as comprehensive toxicological evaluations to assess its safety profile. The compound's unique chemical structure and demonstrated biological effects make it a compelling subject for continued investigation in the chemical biology and pharmaceutical sciences.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)